AxoGen, Inc. to Present at Wedbush PacGrow Healthcare Conference 2016
August 11 2016 - 7:00AM
AxoGen, Inc. (NASDAQ:AXGN), a global leader in innovative surgical
solutions for peripheral nerve injuries, today announced that Karen
Zaderej, President and Chief Executive Officer, will present at the
Wedbush PacGrow Healthcare Conference 2016 in New York City at Le
Parker Meridien Hotel. The presentation is scheduled for Wednesday,
August 17, 2016 at 9:10 am ET (6:10 am PT).
The presentation will be webcast live and can be
accessed through the Investors page at www.axogeninc.com. For those
not available to listen to the live broadcast, a replay will be
archived for 90 days and available through the Investors page on
www.axogeninc.com.
About AxoGen AxoGen (AXGN) is a
global leader in innovative surgical solutions for peripheral nerve
injuries. AxoGen’s portfolio of products includes Avance® Nerve
Graft, an off-the-shelf processed human nerve allograft for
bridging severed nerves without the comorbidities associated with a
second surgical site, AxoGuard® Nerve Connector, a porcine
submucosa extracellular matrix ("ECM") coaptation aid for
tensionless repair of severed nerves, and AxoGuard® Nerve
Protector, a porcine submucosa ECM product used to wrap and protect
injured peripheral nerves and reinforce the nerve reconstruction
while minimizing soft tissue attachments. Along with these core
surgical products, AxoGen also offers AxoTouch™ Two-Point
Discriminator and AcroVal™ Neurosensory & Motor Testing System.
These evaluation and measurement tools assist healthcare
professionals in detecting changes in sensation, assessing return
of sensory, grip and pinch function, evaluating effective treatment
interventions, and providing feedback to patients on nerve
function. The AxoGen portfolio of products is available in the
United States, Canada, the United Kingdom and several European and
international countries.
Cautionary Statements Concerning
Forward-Looking StatementsThis Press Release contains
"forward-looking" statements as defined in the Private Securities
Litigation Reform Act of 1995. These statements are based on
management's current expectations or predictions of future
conditions, events or results based on various assumptions and
management's estimates of trends and economic factors in the
markets in which we are active, as well as our business plans.
Words such as "expects", "anticipates", "intends", "plans",
"believes", "seeks", "estimates", "projects", "forecasts",
"continue", "may", "should", "will" variations of such words and
similar expressions are intended to identify such forward-looking
statements. The forward-looking statements may include, without
limitation, statements regarding our growth, our 2016 guidance,
product development, product potential, financial performance,
sales growth, product adoption, market awareness of our products,
data validation, our visibility at and sponsorship of conferences
and educational events. The forward-looking statements are subject
to risks and uncertainties, which may cause results to differ
materially from those set forth in the statements. Forward-looking
statements in this release should be evaluated together with the
many uncertainties that affect AxoGen's business and its market,
particularly those discussed in the risk factors and cautionary
statements in AxoGen's filings with the Securities and Exchange
Commission. Forward-looking statements are not guarantees of future
performance, and actual results may differ materially from those
projected. The forward-looking statements are representative only
as of the date they are made, and, except as required by law,
AxoGen assumes no responsibility to update any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contacts:
AxoGen, Inc.
Peter J. Mariani, Chief Financial Officer
InvestorRelations@AxoGenInc.com
The Trout Group – Investor Relations
Brian Korb
646.378.2923
bkorb@troutgroup.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Apr 2024 to May 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From May 2023 to May 2024